RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
about
Chemical genetics approaches for selective intervention in epigeneticsSelective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage ProgressionAIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and AtherosclerosisCholesterol, inflammation and innate immunityTargeting bromodomains: epigenetic readers of lysine acetylationTargeting BET bromodomains for cancer treatmentSegmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase AA Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the ComplexBET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphomaSmall-molecule inhibitors of protein-protein interactions: progressing toward the reality.Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.HDL and cognition in neurodegenerative disorders.Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching.Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryPerhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.Investigational therapies for the treatment of atherosclerosis.Emerging drugs for hyperlipidaemia: an update.High-density lipoprotein-based drug discovery for treatment of atherosclerosis.Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).ApoA-I-Directed Therapies for the Management of Atherosclerosis.An evaluation of RVX-208 for the treatment of atherosclerosis.New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.Progress in the Development of non-BET Bromodomain Chemical Probes.Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain.Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.Protein-protein interaction inhibitors: advances in anticancer drug design.Structural features and inhibitors of bromodomains.Targeting Cancer Cells with BET Bromodomain Inhibitors.RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency.A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.Novel Approaches for HDL-Directed Therapies.
P2860
Q26740037-18DA42D4-C390-4920-89FB-718238058E60Q27684429-54000B92-4C43-4EC7-A539-DFBD71476E04Q28083058-09E111B0-A78A-47CF-91E0-B8999CE9A9A3Q28086912-1570DFF6-4151-4ED6-B1CC-A689FF2EFD4EQ28238635-159B5A35-0C09-44FA-92A7-C4E08B5FD00DQ28263519-C5BA9C68-C7BD-46C3-9A3B-85EA2E334B14Q28551713-F08BD93D-633A-41CD-84BF-C35410DB3838Q28552504-48F395F9-824D-40AB-AC37-CA7453593254Q30248629-40AF1DD6-17C4-4C15-ACB8-498A1BFAE3BFQ31124912-BEB96AC5-6EC9-46F9-98CE-96EFB4CCFC62Q33853887-D5A6F7FE-ED7F-481B-9DA8-07E9A09343F4Q34263719-957CDDC2-36BF-4943-846B-56285BF23C8AQ34478968-308D1FC7-00D9-4561-A501-91944A6EDF6FQ34614842-C7E489EC-8912-4DE3-8543-C804DBB45F05Q35220027-84454D16-8C04-4137-B915-3096E6B100FEQ36012341-7FD469D8-268E-4F83-B806-19DB58630B02Q36082984-1AD94569-5652-493E-A91D-DADBD03BF7D5Q36165683-E06271BD-7359-4834-9F53-C03CBCC154D3Q36586506-91E4F8A4-F838-4ABD-81C9-EF9274E551DEQ38214386-EA4BA0AF-6799-425E-89ED-A4671625DB7FQ38263909-0671107C-FF3F-4583-9B8A-CD2AA33C5DEDQ38506490-FA519D2D-6660-460F-A150-529BF1E7BE2CQ38547122-87EFC719-A413-4393-B963-6A2756784B84Q38579703-C586FF01-0398-4B3A-9376-7044101E08FCQ38585825-D7FFACD8-F9B0-4F12-8BCA-678AB9FAC091Q38668610-DB186C5E-1A08-4F9A-87A4-CC3E646BFAC0Q38691377-16E99013-08CA-4781-8C09-A9867A2322F9Q38753477-7448AD9F-18DC-4847-A701-0383CBCED350Q38771703-93E9DFD3-96ED-431A-91CE-460C7362E9B7Q38837561-1286C947-290D-463F-ADBF-3D6ED39E1410Q38935390-7E0FCA6E-426C-48C5-A349-B0653BD9E5E0Q38987705-D7B9A1DA-817E-4560-9BCD-E637480A5E32Q39141456-AB4B0940-7A9C-4CE8-8F05-45CAE698D529Q39250736-64EA9D06-BE7E-45E4-B107-330A12B1CAEEQ41620637-3703E720-B421-468F-AFB6-074E8DE04229Q42131230-A7647B9D-6499-4F22-90BC-AED5082285D6Q42198254-38272446-9697-49C4-B95A-80D78F37780AQ47120827-2946A844-1471-4407-B746-DB18A01A2565Q47400790-D4776287-630D-487B-8AC3-E6DE8930A1C1Q47441104-114DA075-B3EB-47F2-B082-FEC2F74F2268
P2860
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@ast
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en-gb
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@nl
type
label
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@ast
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en-gb
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@nl
altLabel
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
@en
prefLabel
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@ast
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en-gb
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@nl
P2093
P2860
P3181
P1433
P1476
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist
@en
P2093
Adam Stein
Andre White
Emily M Gesner
Eric Campeau
Eric Fontano
Gregory S Wagner
Henrik C Hansen
Kevin G McLure
Laura Tsujikawa
Norman C W Wong
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0083190
P407
P577
2013-01-01T00:00:00Z